Search Results
Jul 12, 2026, 12:00 ET A New Approach to Treating Brain Cancer: HDT Bio Launches Canadian Clinical Program at McGill University
has engaged Northern RNA Inc. of Calgary as its Canadian GMP manufacturing partner. Northern RNA is a world-class nucleic acid contract manufacturer."This is exactly the kind of program Northern RNA was built to support," said Jared Davis, President and CEO of Northern RNA Inc. "Canadian patients
More news about: HDT Bio Corp.
Jul 09, 2026, 16:15 ET /C O R R E C T I O N -- RyboDyn/
targeted by decoding the dark proteome: cryptic proteins missed by conventional and next-generation sequencing. Powered by RyboCypher™, its proprietary RNA sequencing and AI-enabled discovery platform, the company identifies novel therapeutic targets directly from patient samples. By discovering highly prevalent,
More news about: RyboDyn
Jul 09, 2026, 13:06 ET GEMMABio Awarded ARPA-H Funding to Pursue Innovative Base-editing Strategy for Rare Liver Diseases
novel and powerful base-editing approach that can be applied across diverse mutations and genetic diseases where the only unique component is guide RNA (gRNA). We believe these attributes may permit significant cost reductions and have the potential to increase access around the world.""Profluent
More news about: GEMMA Biotherapeutics
Jul 09, 2026, 12:58 ET Renew Biotechnologies Unifies Wasatch BioLabs and Resonant Under One Brand to Advance Sequencing-Based Diagnostics
clinical impact."The unified Renew Biotechnologies products and services will continue to expand across long-read and native-read sequencing, RNA therapeutic quality control, methylation technologies, pharmacogenomics, telomere sequencing, blood-based diagnostics, and custom assay development.Renew's
More news about: Renew Biotechnologies
Jul 08, 2026, 09:00 ET Co-Diagnostics Invited to Participate in NPOC Tuberculosis Diagnostics Workshop in Bangkok, Thailand
technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory
More news about: Co-Diagnostics
Jul 07, 2026, 10:01 ET Gene Editing Market to Reach US$30.5 Billion by 2033 as Precision Medicine and CRISPR Innovation Accelerate Growth - Persistence Market Research
has accelerated adoption among biotechnology companies and academic laboratories worldwide. Automation, artificial intelligence, and improved guide RNA design are reducing development timelines while increasing editing accuracy. Enhanced viral and non-viral delivery systems further improve treatment
More news about: Persistence Market Research Pvt. Ltd.
Jul 07, 2026, 10:00 ET New England Biolabs® launches the NEBNext® Companion Module for Oxford Nanopore Technologies® Direct RNA Sequencing
launched the NEBNext Companion Module for Oxford Nanopore Technologies Direct RNA Sequencing. The companion module contains the NEB reagents recommended by Oxford Nanopore for execution of the Direct RNA Sequencing workflow (RNA004 sequencing kit), providing a simple and convenient format for scientists performing
More news about: New England Biolabs, Inc.
Jul 06, 2026, 08:45 ET NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"
target several key mechanisms of ALS and AD, that contribute to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid ("RNA") regulation to potentially inhibit the progression of ALS and AD.About ALSAmyotrophic lateral sclerosis ("ALS") is an incurable
More news about: NeuroSense
Jul 03, 2026, 10:30 ET Biomarkers Market worth $112.10 billion by 2031 | MarketsandMarkets™
to 2031. This high-throughput DNA and RNA sequencing method can process millions of fragments simultaneously, enabling faster, more comprehensive genomic profiling. It supports key biomarker applications, including whole-genome/exome sequencing, gene panels, RNA sequencing, and single-cell analysis,
More news about: MarketsandMarkets
Jul 02, 2026, 20:00 ET Brii Bio Announces Topline End-of-Treatment Data from Phase 2b ENRICH and ENHANCE Studies for the Treatment of Chronic Hepatitis B
Designation.About ElebsiranElebsiran is an investigational subcutaneously administered HBV-targeting siRNA designed to degrade HBV RNA transcripts and limit the production of hepatitis B surface antigen. It has the potential to have direct antiviral activity against HBV and HDV. It is
More news about: Brii Biosciences Limited
Jul 02, 2026, 10:53 ET Ribo und Madrigal erreichen ersten wichtigen Meilenstein bei der Weiterentwicklung neuartiger siRNA-Therapien für MASH
Diese Partnerschaft unterstreicht deutlich das gemeinsame Engagement von Ribo und Madrigal für die Weiterentwicklung innovativer RNA-Therapeutika zur Behandlung von Lebererkrankungen, wobei der Schwerpunkt auf der metabolisch bedingten Steatohepatitis (MASH) liegt – einem Bereich mit
More news about: Suzhou Ribo Life Science Co., Ltd.
Jul 02, 2026, 06:30 ET Partner Therapeutics Announces Publication of Results From the eNRGy Trial of Zenocutuzumab in Patients with NRG1+ Cholangiocarcinoma in Journal of Clinical Oncology (JCO)
cholangiocarcinoma, of whom 19 were evaluable for efficacy. Most patients were pre-treated, with a median of one prior line of therapy (range up to 6). Notably, RNA-based next-generation sequencing (NGS) identified 100% of NRG1 fusions, compared with 29% detected by DNA-based testing.The investigator-assessed
More news about: Partner Therapeutics, Inc.
Jul 02, 2026, 06:00 ET Circular Genomics Unveils Its CircPATH™ Platform Following Landmark Nature Medicine Study Demonstrating Breakthrough Performance in Early Detection of Alzheimer's Disease
today announced the launch of CircPATH™, the company's proprietary circular RNA discovery and validation engine, following the publication of landmark findings in Nature Medicine demonstrating that blood-based circular RNA (circRNA) biomarkers can predict Alzheimer's disease (AD) progression with
More news about: Circular Genomics
Jul 01, 2026, 21:39 ET Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH
This partnership fully underscores Ribo's and Madrigal's joint commitment to advancing cutting-edge RNA therapeutics for liver diseases, with a primary focus on metabolic dysfunction-associated steatohepatitis (MASH), a field with tremendous unmet medical
More news about: Suzhou Ribo Life Science Co., Ltd.
Jul 01, 2026, 21:19 ET Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH
This partnership fully underscores Ribo's and Madrigal's joint commitment to advancing cutting-edge RNA therapeutics for liver diseases, with a primary focus on metabolic dysfunction-associated steatohepatitis (MASH), a field with tremendous unmet medical
More news about: Suzhou Ribo Life Science Co., Ltd.
Jul 01, 2026, 16:28 ET Skyhawk Therapeutics divulga os resultados dos subcomponentes do cUHDRS após doze meses de seu ensaio clínico de Fase 1/2 com o SKY-0515 na doença de Huntington
Therapeutics, Inc., uma empresa de biotecnologia em fase clínica que desenvolve novas terapias com moléculas pequenas destinadas a modular alvos de RNA, anuncia dados dos subcomponentes do cUHDRS provenientes da análise intermediária de doze meses dos dados de seu ensaio clínico de Fase 1/2 que avalia
More news about: Skyhawk Therapeutics
Jul 01, 2026, 11:21 ET MGI Tech Launches Go Spatial in Europe and Expands STOmics Partner Network at STOC 2026
neuroscience, immunology, infectious disease, plant biology, and developmental biology. The workflow streamlines post-imaging sample preparation from RNA capture to cDNA with minimal hands-on time for both fresh frozen and FFPE samples, processing up to 12 cm² of fresh frozen tissue or 8 cm² of FFPE tissue
More news about: MGI Tech Co., Ltd.
Jul 01, 2026, 09:00 ET Co-Diagnostics Completes Clinical and Analytical Studies in Preparation for FDA 510(k) Submission of Upper Respiratory Point-of-Care Test
technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory
More news about: Co-Diagnostics
Jul 01, 2026, 08:50 ET Skyhawk Therapeutics veröffentlicht die Ergebnisse der cUHDRS-Unterkomponenten nach zwölf Monaten aus seiner klinischen Phase-1/2-Studie mit SKY-0515 bei der Huntington-Krankheit
Therapeutics, Inc., ein im klinischen Stadium tätiges Biotechnologieunternehmen, das neuartige kleinmolekulare Therapien zur Modulation von RNA-Zielstrukturen entwickelt, kündigt die Veröffentlichung von Daten zu den cUHDRS-Unterkomponenten aus der Zwölfmonats-Zwischenanalyse der Daten seiner
More news about: Skyhawk Therapeutics
Jul 01, 2026, 08:30 ET Caris Life Sciences Launches Caris Detect, the World's Most Sensitive and Comprehensive Multi-Cancer Early Detection Blood Test
approaches that evaluate only a narrow subset of genomic changes, Caris Detect examines the full breadth of genomic and molecular signals, including DNA, RNA and other biological patterns. This deeper, more comprehensive analysis is designed to improve confidence in identifying cancer signals at their earliest
More news about: Caris Life Sciences
Jun 30, 2026, 10:17 ET Tsingke Biotech Hosts Shanghai Salon on Oligonucleotide Drugs, Spotlighting Next-Gen RNA Therapeutics
multimedia:https://www.prnewswire.com/news-releases/tsingke-biotech-hosts-shanghai-salon-on-oligonucleotide-drugs-spotlighting-next-gen-rna-therapeutics-302811506.htmlSOURCE
More news about: Tsingke Biotech
Jun 30, 2026, 10:17 ET Tsingke Biotech Hosts Shanghai Salon on Oligonucleotide Drugs, Spotlighting Next-Gen RNA Therapeutics
content:https://www.prnewswire.co.uk/news-releases/tsingke-biotech-hosts-shanghai-salon-on-oligonucleotide-drugs-spotlighting-next-gen-rna-therapeutics-302811515.html
More news about: Tsingke Biotech
Jun 30, 2026, 10:00 ET Zymo Research Joins BLOODPAC to Advance Standards for Liquid Biopsy
Zymo Research brings more than 30 years of expertise in molecular biology and genomics, with core strengths in sample collection and preservation, DNA/RNA purification, epigenetics, microbiomics, and next-generation sequencing research. Through its participation in BLOODPAC, Zymo Research will lend molecular
More news about: Zymo Research Corp.
Jun 30, 2026, 07:05 ET Skyhawk Therapeutics Releases Twelve-Month cUHDRS Subcomponent Results from its Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease
Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate RNA targets, announces cUHDRS subcomponent data from the twelve-month interim analysis of data from its Phase 1/2 clinical trial evaluating SKY-0515, an
More news about: Skyhawk Therapeutics
Jun 30, 2026, 07:00 ET Skyhawk Therapeutics Releases Twelve-Month cUHDRS Subcomponent Results from its Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease
Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate RNA targets, announces cUHDRS subcomponent data from the twelve-month interim analysis of data from its Phase 1/2 clinical trial evaluating SKY-0515, an
More news about: Skyhawk Therapeutics